Starting at the full target dose would produce maximum GI effects immediately, reducing tolerability and potentially causing research subjects to discontinue
Many patients assume these medications are out of reach or do not know their plan may cover them
investigated the impact of liraglutide 3 mg in 14 obese patients with HS, finding significant reductions in BMI, waist circumference, CRP, homocysteine, and plasma cortisol after 3 months treatment
As of 2025, Retatrutide has completed Phase 2 trials with landmark results and is currently in Phase 3 trials
But insurance companies want to keep costs down themselves, so many won't cover them for weight loss, or require patients to jump through frustrating hoops to get approval for coverage
Thats reassuring because it suggests this isnt an immune system problem, Friedman says